Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Monopar Therapeutics Inc MNPR

Healthcare Biotechnology
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MNPR)

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

GlobeNewswire November 8, 2024

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

GlobeNewswire October 30, 2024

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

GlobeNewswire October 28, 2024

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire October 28, 2024

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

GlobeNewswire October 24, 2024

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

GlobeNewswire October 22, 2024

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

GlobeNewswire October 15, 2024

Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers

GlobeNewswire October 7, 2024

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

GlobeNewswire September 12, 2024
View More News ››

Opinion & Analysis (NDAQ:MNPR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MNPR)

Monopar Therapeutics Reports Second Quarter 2024&#xA0;Financ

Just In: $MNPR Monopar Therapeutics Reports Second Quarter 2024&#xA0;Financial Results and Recent DevelopmentsInitiated and...
whytestocks - August 9, 2024

Monopar Therapeutics Inc. (NASDAQ:MNPR): Laser-Focused on Ad

http://beyondspx.com/2024/08/02/monopar-therapeutics-inc-nasdaqmnpr-laser-focused-on-advancing-its-promising-radiopharmaceutical-pipeline...
MikeTester - August 3, 2024

Monopar Announces First Patient Enrolled in First-in-Human P

Just In: $MNPR Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101...
whytestocks - July 9, 2024

Monopar Announces CFO Succession

NEWS: $MNPR Monopar Announces CFO SuccessionWILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a...
whytestocks - May 24, 2024

Monopar Announces Filing of Patent Protecting MNPR-101 Radio

Just In: $MNPR Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization FindingsWILMETTE, Ill., April 16, 2024...
whytestocks - April 16, 2024

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical

Breaking News: $MNPR Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical TrialWILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE...
whytestocks - February 27, 2024
View more Bullboard ››

Fineqia International Inc.

Fineqia International Inc.

Fineqia International Inc. is a digital asset business that builds and targets investments in early and growth stage ...
View More »